Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.99 USD
Change Today +0.11 / 0.36%
Volume 213.2K
MR On Other Exchanges
Symbol
Exchange
New York
Singapore
Mexico
Frankfurt
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

mindray medical intl ltd-adr (MR) Snapshot

Open
$30.89
Previous Close
$30.88
Day High
$31.03
Day Low
$30.84
52 Week High
03/5/15 - $33.83
52 Week Low
01/6/15 - $25.90
Market Cap
3.6B
Average Volume 10 Days
334.4K
EPS TTM
$1.66
Shares Outstanding
88.2M
EX-Date
03/17/15
P/E TM
18.7x
Dividend
$0.40
Dividend Yield
1.29%
Current Stock Chart for MINDRAY MEDICAL INTL LTD-ADR (MR)

mindray medical intl ltd-adr (MR) Related Businessweek News

View More BusinessWeek News

mindray medical intl ltd-adr (MR) Details

Mindray Medical International Limited develops, manufactures, and markets medical devices worldwide. The company operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. The Patient Monitoring and Life Support Products segment offers monitoring devices that track the physiological parameters of patients, such as heart rate, blood pressure, respiration, and temperature. Its products include single and multiple-parameter monitors; mobile and portable multifunction monitors; central stations that can collect and display multiple patient data on a single screen; electro-cardiogram monitoring devices; and veterinary monitoring devices. This segment also provides anesthesia machines; defibrillators; surgical equipment, including surgical beds, and surgical lights ceiling pendants; syringes and infusion pumps; and ventilators. The In-Vitro Diagnostic Products segment provides data and analysis on blood, urine, and other bodily fluid samples for clinical diagnosis and treatment; and in-vitro diagnostic products for laboratories, clinics, and hospitals to perform analysis to detect and quantify substances in patient samples. Its product portfolio consists of hematology analysis, biochemistry analysis, immunoassay analysis, flow cytometric analysis, coagulation analysis, urine sediment analysis and microbiology analysis; and reagents used in in-vitro diagnostic products. The Medical Imaging Systems segment offers ultrasound systems used in medical fields, such as urology, gynecology, obstetrics, and cardiology; digital radiography systems; and magnetic resonance imaging systems. The company also provides orthopedic products, endoscope devices, and healthcare IT solutions. It markets and sells its products through distributors, as well as directly to hospitals and government agencies. The company was founded in 1991 and is headquartered in Shenzhen, the People’s Republic of China.

8,277 Employees
Last Reported Date: 04/16/15
Founded in 1991

mindray medical intl ltd-adr (MR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mindray medical intl ltd-adr (MR) Key Developments

Mindray Medical International Limited Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Mindray Medical International Limited announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. The company reported net revenues of $399.0 million for the fourth quarter of 2014, an 8.3% increase from the fourth quarter of 2013. Operating income for the fourth quarter of 2014 was $53.4 million, a 1.0% decrease from the fourth quarter of 2013. Non-GAAP operating income for the fourth quarter of 2014 was $61.9 million, an 18.3% decrease from the fourth quarter of 2013. Fourth quarter 2014 Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) increased 7.1% year-over-year to $74.4 million. Net income decreased 30.9% from a year ago to $52.0 million. Fourth quarter 2014 non-GAAP net income decreased 19.1% year-over-year to $59.7 million. Basic and diluted earnings per share were both $0.44, compared to $0.64 and $0.63 respectively in the fourth quarter of 2013. Fourth quarter 2014 basic and diluted non-GAAP earnings per share were $0.51 and $0.50, compared to $0.62 for both in the fourth quarter of 2013. Excluding the tax benefits, diluted non-GAAP earnings per share was $0.49 in the fourth quarter of 2014, compared to $0.55 in the fourth quarter of 2013. Income from operations was $53.418 million against $53.970 million a year ago. EBIT was $59.055 million against $55.106 million a year ago. Net cash provided by operating activities was $140.665 million against $122.196 million a year ago. Capital expenditure was $28.016 million against $41.901 million a year ago. Non-GAAP operating income was $61.9 million against $75.8 million a year ago The company reported net revenues of $1.3 billion for the full year 2014, a 9.0% increase from the full year 2013. Full year 2014 EBITDA decreased 3.1% to $254.9 million from full year 2013. Full year 2014 net income decreased 14.0% to $193.3 million from a year ago. Full year 2014 non-GAAP net income decreased 13.6% to $228.2 million from 2013. Excluding tax benefits, full year 2014 non-GAAP net income decreased 6.1% year-over-year to $222.1 million. Full year 2014 diluted earnings per share decreased 12.8% to $1.63 from $1.87 in 2013. Full year 2014 non-GAAP diluted earnings per share decreased 12.4% to $1.93 from $2.20 in 2013. Excluding the tax benefits, full year 2014 diluted non-GAAP earnings per share was $1.88, down 4.8% compared to $1.97 in 2013. Income from operations was $192.526 million against $210.224 million a year ago. EBIT was $196.192 million against $208.312 million a year ago. Net cash provided by operating activities was $330.454 million against $307.918 million a year ago. Capital expenditure was $107.124 million against $109.080 million a year ago. Non-GAAP operating income was $230.3 million against $252.7 million a year ago. The company anticipates its full year 2015 net revenues to grow by a mid-single digit percentage over its full year 2014 net revenues. The company also expects its full year 2015 non-GAAP net income to decrease by a high-single digit percentage over its full year 2014 non-GAAP net income. The company expects its capital expenditure for 2015 to be around $150 million.

Mindray Medical International Limited Declares Cash Dividend for the Full Year 2014, Payable on or Around March 31, 2015; Appoints Li Xiting as Executive Chairman of the Board

Mindray Medical International Limited announced that its board of directors declared a cash dividend on its ordinary shares of $0.40 per share, based on the company's net income for the full year 2014. The cash dividend will be payable on or around March 31, 2015 to shareholders of record as of March 19, 2015. The company announced that it has appointed Li Xiting as executive chairman of the board. Xiting is currently serving as the company's president, co-chief executive officer and director. Xu Hang will continue to serve as chairman of the board.

Mindray Medical International Limited Announces Releases its New-Generation TE7 Ultrasound System

Mindray announced that its new-generation TE7 ultrasound system has been officially released. The system will be showcased for the first time at the European Congress of Radiology (ECR 2015) in Viennabetween March 5 and March 8. It is scheduled for release in the North American market in mid-2015. The TE7 combines an intuitive user interface with a simplified workflow, an innovative ergonomic design, and focused exam presets. It is designed to provide superior-quality imaging to enable clinicians to make patient-care decisions more quickly. The TE7 takes only three seconds to boot up from standby and is equipped with other enhanced features such as iNeedleâ ¢ (enhanced visualization for needles), iZoomâ ¢ (full screen image), and Smart Track (continuous tracking of color flow and optimization of real-time scanning).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MR:US $30.99 USD +0.11

MR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CAS Medical Systems Inc $1.34 USD +0.06
Hutchinson Technology Inc $1.97 USD -0.39
Omron Corp ¥5,410 JPY -110.00
OSI Systems Inc $67.19 USD -0.02
Sysmex Corp ¥6,530 JPY -110.00
View Industry Companies
 

Industry Analysis

MR

Industry Average

Valuation MR Industry Range
Price/Earnings 19.0x
Price/Sales 2.8x
Price/Book 2.3x
Price/Cash Flow 18.8x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MINDRAY MEDICAL INTL LTD-ADR, please visit www.mindray.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.